Ritholtz Wealth Management purchased a new stake in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund purchased 12,859 shares of the biopharmaceutical company’s stock, valued at approximately $231,000.
Other hedge funds and other institutional investors have also bought and sold shares of the company. FDx Advisors Inc. acquired a new position in shares of Dicerna Pharmaceuticals in the 1st quarter valued at about $38,000. Pacer Advisors Inc. acquired a new position in Dicerna Pharmaceuticals during the 3rd quarter valued at about $55,000. Nisa Investment Advisors LLC lifted its stake in shares of Dicerna Pharmaceuticals by 303.2% in the 3rd quarter. Nisa Investment Advisors LLC now owns 3,125 shares of the biopharmaceutical company’s stock worth $56,000 after acquiring an additional 2,350 shares during the period. Macquarie Group Ltd. acquired a new stake in shares of Dicerna Pharmaceuticals in the 2nd quarter worth approximately $62,000. Finally, US Bancorp DE lifted its stake in shares of Dicerna Pharmaceuticals by 35.6% in the 2nd quarter. US Bancorp DE now owns 4,035 shares of the biopharmaceutical company’s stock worth $102,000 after acquiring an additional 1,060 shares during the period. 83.50% of the stock is owned by institutional investors and hedge funds.
DRNA traded up $0.21 on Monday, reaching $19.60. 2,830 shares of the company traded hands, compared to its average volume of 651,857. The stock’s 50 day moving average price is $18.79 and its 200-day moving average price is $20.98. Dicerna Pharmaceuticals Inc has a 52-week low of $11.75 and a 52-week high of $27.68. The company has a market cap of $1.44 billion, a price-to-earnings ratio of -10.95 and a beta of 1.47.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.43) EPS for the quarter, missing the Zacks’ consensus estimate of $0.11 by ($0.54). Dicerna Pharmaceuticals had a negative net margin of 139.27% and a negative return on equity of 79.65%. The company had revenue of $40.45 million for the quarter, compared to analysts’ expectations of $76.04 million. On average, sell-side analysts anticipate that Dicerna Pharmaceuticals Inc will post -0.69 earnings per share for the current year.
A number of research firms recently commented on DRNA. BidaskClub upgraded shares of Dicerna Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, September 19th. HC Wainwright boosted their target price on shares of Dicerna Pharmaceuticals from $32.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, August 7th. ValuEngine upgraded shares of Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, August 14th. Zacks Investment Research downgraded shares of Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, August 12th. Finally, B. Riley reiterated a “buy” rating and issued a $30.00 target price on shares of Dicerna Pharmaceuticals in a report on Monday, August 10th. Two investment analysts have rated the stock with a sell rating and twelve have issued a buy rating to the stock. Dicerna Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $34.27.
In other Dicerna Pharmaceuticals news, insider Bob D. Brown sold 8,185 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $22.48, for a total value of $183,998.80. Following the completion of the sale, the insider now directly owns 13,185 shares of the company’s stock, valued at $296,398.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Douglas Fambrough bought 10,000 shares of the firm’s stock in a transaction on Tuesday, September 1st. The stock was acquired at an average cost of $18.06 per share, with a total value of $180,600.00. Following the completion of the transaction, the chief executive officer now directly owns 22,300 shares of the company’s stock, valued at $402,738. The disclosure for this purchase can be found here. Insiders have sold 37,635 shares of company stock worth $801,882 over the last ninety days. 11.30% of the stock is currently owned by insiders.
Dicerna Pharmaceuticals Profile
Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.
Further Reading: What is the significance of the death cross?
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.